The Role of Hormonal Therapy in Gynecological Cancers—Current Status and Future Directions

Katrin Marie Sjoquist, Julie Martyn, Richard J. Edmondson, Michael Friedländer
In: International Journal of Gynecological Cancer · 2011 · vol. 21(7) , pp. 1328–1333 · doi:10.1097/igc.0b013e31821d6021 · PMID:21720258 · W2037718360
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This review examines the current applications and future prospects of hormonal therapy in managing gynecological cancers.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Many gynecological cancers, including epithelial and stromal ovarian cancers; endometrial carcinomas; and some gynecological sarcomas, in particular endometrial stromal sarcomas, express estrogen and/ or progesterone receptors. Hormonal therapy, typically progestogens or tamoxifen, is commonly prescribed to patients with potentially hormone-sensitive recurrent or metastatic gynecological cancers with very variable response rates and clinical benefit reported. Aromatase inhibitors are now widely used to treat postmenopausal women with hormone receptor-positive breast cancers as they have greater activity than tamoxifen and are generally better tolerated. The role of aromatase inhibitors in gynecological cancers is uncertain and has not been well studied, although they do appear to be active. The current evidence to support the use of hormonal therapies including aromatase inhibitors in gynecological cancers is reviewed, and the gaps in our knowledge highlighted.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (34)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK